Cancer Research

{
  "result": " The most meaningful development this tick is not a confirmed gene-cancer link, but the discovery of a clear, dual-track path to break the mission’s “zero-edge barrier.” After surveying the existing landscape, the AI determined that low-density lipoprotein receptor (*LDLR*) regulation in the liver represents the most immediate, tractable entry point for proving a causal connection to colorectal cancer subtype risk, while prostaglandin-endoperoxide synthase 2 (*PTGS2*, also known as COX-2) offers a complementary route through the tumor’s stromal and immune microenvironment. This strategic clarity is itself a finding: the precise causal chains connecting metabolic and inflammatory genetics to microsatellite-stable (MSS) versus microsatellite-unstable (MSI) colorectal tumors remain genuinely unmapped in current databases, confirming an open scientific frontier rather than a settled question.\n\nColorectal cancer is not a single disease. MSS tumors, which are typically chromosomally unstable, behave differently from MSI-high tumors, which are hypermutated and more immunogenic. To move beyond simple association, this mission seeks “hardened causal edges”—directional evidence that a specific gene, acting through a specific tissue, actually helps cause one subtype and not the other. For *LDLR*, the hypothesis is that genetically driven cholesterol metabolism in the liver alters the intestinal environment to favor MSS tumor development. For *PTGS2*, the hypothesis is that inflammatory signaling in colon stromal cells creates genetic dependencies that can be exploited differently in MSS versus MSI contexts, particularly when combined with mutations in the WNT/APC pathway that drives most colorectal cancers.\n\nThis tick focused on building the foundational pipelines required to test these hypotheses rigorously. The AI designed a three-pronged investigation: first, validating genetic instruments for *LDLR* using liver gene-expression data from GTEx and testing whether those same DNA variants statistically overlap—or “colocalize”—with colorectal cancer risk signals in multi-ancestry genome-wide association studies; second, mapping *PTGS2* regulation in colon tissue and single-cell stromal atlases, then querying CRISPR co-dependency databases to see if shutting down *PTGS2* kills MSS cells selectively when WNT pathway genes are also disrupted; and third, constructing metabolic polygenic scores—aggregating thousands of small genetic effects for obesity and dyslipidemia—to test whether a person’s overall metabolic genetic background modifies the impact of *LDLR* or *PTGS2* variants on cancer risk.\n\nNo hardened causal edges were confirmed this tick; the knowledge base remains at zero validated relations. However, the AI refined five focused hypotheses and deliberately archived distracting tangents—such as PCSK9 and generic drug-repurposing screens—to protect focus. This absence of findings is scientifically informative: it confirms that the proposed connections between hepatic lipid genetics, stromal inflammation, and CRC subtypes have not yet been subjected to the specific combination of tissue-specific colocalization, stratified Mendelian randomization, and subtype-specific CRISPR analysis that the mission demands. The groundwork is now laid for direct computational testing.\n\nLooking ahead, the mission will execute colocalization at the *LDLR* locus (19p13.3) to determine whether liver gene-expression signals and colorectal cancer risk signals share a single causal variant; query DepMap for *PTGS2* synthetic lethal interactions with WNT pathway genes in MSS versus MSI cell lines; and test whether metabolic polygenic scores modify these genetic effects across ancestries in UK Biobank, FinnGen, and East Asian cohorts. Overall confidence in the direction is cautiously high: by tethering every query to tissue-appropriate instruments and subtype-specific cellular contexts, the approach avoids the generic associations that have cluttered broader cancer genetics. Still, these computational candidates remain hypotheses until they pass experimental validation.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 5
}